Table 1.
Univariate and multivariate analysis for PFS in EGFR–TKIs monotherapy cohort.
| Characteristics | Univariate analysis HR (95% CI) | p-value | Multivariate analysis HR (95% CI) | p-value |
|---|---|---|---|---|
| Sex male/female | 1.398 (0.817–2.392) | 0.222 | ||
| Age ≥ 60/ < 60 years old | 1.008 (0.584–1.740) | 0.976 | ||
| Smoking history yes/no | 1.394 (0.798–2.435) | 0.244 | ||
| TNM stage IV/III | 1.514 (0.735–3.119) | 0.260 | ||
| ECOG ≥ 2/0-1 | 14.508 (3.445–61.096) | < 0.001 | 17.101 (3.814–76.678) | < 0.001 |
| Brain metastasis yes/no | 0.603 (0.256–1.423) | 0.248 | ||
| Liver metastasis yes/no | 1.036 (0.464–2.310) | 0.932 | ||
| Bone metastasis yes/no | 1.043 (0.598–1.819) | 0.883 | ||
| PD-L1 positive/negative | 2.147 (1.178–3.915) | 0.013 | 2.222 (1.216–4.060) | 0.009 |
HR Hazard ratio, TNM Tumor node metastasis, ECOG Eastern Cooperative Oncology Group.